CClinicalTrials.gg
Sign In
Active, not recruitingNCT06925828Updated Apr 13, 2025

Application of in Vivo Splitting Technique in Adult Liver Transplantation

An observational study in Liver Transplantation, sponsored by Ningbo Medical Center Lihuili Hospital. Active, not recruiting at 1 site in China. Open to participants aged 16 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Ningbo Medical Center Lihuili Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2025, 9 months ago, but the record still lists the study as active, not recruiting.
Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
500
Ages
16 Years to 75 Years
Sex
All
01

Study summary

The feasibility of split liver transplantation (SLT) remains controversial. This study aimed to evaluate the outcomes of SLT in adult recipients and to identify specific areas of improvements. A retrospective analysis was conducted on adults who underwent full size SLT between January 2021 and December 2023. The short-term outcomes of these patients who underwent SLT were compared with those of patients who underwent whole liver transplantation (WLT) during the same period.

02

Conditions studied

  • Liver Transplantation

Keywords

  • Split liver transplantation
  • Whole liver transplantation
  • Short-term Outcomes
  • Surgical complications
  • Morbidity and Mortality
03

In context

Lead sponsor

Ningbo Medical Center Lihuili Hospital is the lead sponsor of 15 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult recipients who underwent SLT or WLT

Inclusion criteria

  • For the donor graft:

    1. age of 18-60 years;
    2. BMI of 19-28 kg/m2;
    3. hemodynamic stability or use of a single vasoactive drug with a small dosage (norepinephrine ≤ 0.1 μg/kg/min or dopamine ≤ 5 μg/kg/min);
    4. liver steatosis ≤ 10%;
    5. liver functional indicators (ALT, AST, total bilirubin quantification) ≤ 3 times the normal value;
    6. blood sodium ≤ 160 mmol/L;

For the SLT recipients

  1. Patients who had registered in the China Organ Transplant Response Systems.
  2. Initial liver transplantation.
  3. Graft-to-Recipient Weight Ratio (GRWR) ≥ 1%.

Exclusion criteria

Exclusion Criteria:

  • For the donor graft

    1. uncontrollable infection
    2. significant vascular and biliary variation.

For the recipients

  1. Severe portal hypertension.
  2. Significant vascular variation.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
500 participants (actual)
Patient registry
No

Groups and cohorts

  • SLT group

    Adult recipients who underwent split liver transplantation

    Other: No intervention

  • WLT group

    Adult recipients who underwent whole liver transplantation

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Overall survival

    the overall survival of liver transplant recipient during study period

    Time frame: 2021.01.01-2025.12.31

Secondary outcomes

  1. Postoperative complications

    Postoperative complications of liver transplant recipient during study period

    Time frame: 2021.01.01-2025.12.31

07

Study locations

1 site
  • Ningbo Medical Centre Lihuili Hospital
    Ningbo, Zhejiang 315000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06925828
Lead sponsor
Ningbo Medical Center Lihuili Hospital
Responsible party
lucaide (Professor, Ningbo Medical Center Lihuili Hospital) — Principal investigator
First posted
Apr 13, 2025
Start date
Jan 1, 2021
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 13, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Ningbo Medical Center Lihuili Hospital

Start the discussion